At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 133 enrolled
Drug / intervention
Docetaxel-Carboplatindrug
Likely dose
Docetaxel-Carboplatin 75 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer
In Brief
A Phase 4 clinical trial evaluating Docetaxel-Carboplatin for Non-small Cell Lung Cancer. Completed, enrolled 133 participants across 12 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether it is safe to treat lung cancer patients who have undergone an attempt at curative resection with the combination of docetaxel and carboplatin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina, United States
CollaboratorsSanofi
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2009
Enrollment StartMay 2009
Primary CompletionSep 2012
Study CompletionDec 2012
TodayJul 2026
First PostedApr 20, 2009
Enrollment StartMay 1, 2009
Primary CompletionSep 1, 2012
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 17.2 years ago
Interventions
Docetaxel-Carboplatindrug
Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin AUC 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses